In his debut blog, Nick Meader tackles a huge umbrella review of youth mental health interventions, which presents the efficacy and acceptability of 72 different approaches to help children and young people.
[read the full story...]
Rudiger Pittrof and Elana Covshoff from SHRINE (Sexual and Reproductive Health Rights, Inclusion and Empowerment) explore a recent review, which looks at the impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.
[read the full story...]
Carmine Pariante is positive about a recent systematic review and meta-analysis of antidepressants for the treatment of depression in schizophrenia.
[read the full story...]
Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.
[read the full story...]
Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.
[read the full story...]
Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.
[read the full story...]
Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.
[read the full story...]
Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?
[read the full story...]
Murtada Alsaif summarises a small cohort study that uses shotgun mass spectrometry proteomic profiling to unravel the molecular pathways involved with antipsychotic response in people with schizophrenia.
[read the full story...]
Helen Bould appraises a recent meta-analysis of second-generation antipsychotics for anorexia nervosa, which finds that the drugs don’t lead to weight gain or improve eating disorder symptoms. So why are antipsychotics being used in this group of patients?
[read the full story...]
